Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases

[1] Soffietti R(2017)Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) Neuro Oncol 19 162-174

[2] Abacioglu U(2010)Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin Cancer Res 16 5664-5678

[3] Baumert B(2020)Brain metastasis Nat Rev Cancer 20 4-11

[4] Combs SE(2005)Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group J Clin Oncol 23 2955-2961

[5] Kinhult S(2017)Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study Neuro Oncol 19 1511-1521

[6] Kros JM(2011)Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis J Clin Oncol 29 279-286

[7] Lockman PR(2019)Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG Oncology/RTOG 0214 phase 3 randomized clinical trial JAMA Oncol 5 847-855

[8] Mittapalli RK(2020)Current approaches to the management of brain metastases Nat Rev Clin Oncol 17 279-299

[9] Taskar KS(2015)Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99–1 randomized clinical trial JAMA Oncol 1 457-464

[10] Rudraraju V(2016)EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases J Thorac Oncol 11 1718-1728

[1] Soffietti R(2017)Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) Neuro Oncol 19 162-174

[2] Abacioglu U(2010)Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin Cancer Res 16 5664-5678

[3] Baumert B(2020)Brain metastasis Nat Rev Cancer 20 4-11

[4] Combs SE(2005)Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group J Clin Oncol 23 2955-2961

[5] Kinhult S(2017)Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study Neuro Oncol 19 1511-1521

[6] Kros JM(2011)Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis J Clin Oncol 29 279-286

[7] Lockman PR(2019)Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG Oncology/RTOG 0214 phase 3 randomized clinical trial JAMA Oncol 5 847-855

[8] Mittapalli RK(2020)Current approaches to the management of brain metastases Nat Rev Clin Oncol 17 279-299

[9] Taskar KS(2015)Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99–1 randomized clinical trial JAMA Oncol 1 457-464

[10] Rudraraju V(2016)EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases J Thorac Oncol 11 1718-1728